Welcome to chemicalbook!
Chinese English Japanese Germany Korea
+1 (818) 612-2111
18162-48-6872-50-4Methylene ChloridenaphthaleneTHFTitanium Dioxide
Structured search
Inquriy
Try our best to find the right business for you.
Messages
Do not miss inquiry messages Please log in to view all inquiry messages.
My chemicalbook My chemicalbook

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >API>Nervous system drugs>Antiepileptic and anticonvulsant> 2-Propylpentanoic acid
2-Propylpentanoic acid
  • 2-Propylpentanoic acid
  • 2-Propylpentanoic acid

2-Propylpentanoic acid NEW

Price $5 $0.1
Package 1KG 1000KG
Min. Order: 1KG
Supply Ability: g-kg-tons, free sample is available
Update Time: 2024-04-16

Product Details

Product Name: 2-Propylpentanoic acid CAS No.: 99-66-1
Min. Order: 1KG Purity: 99%
Supply Ability: g-kg-tons, free sample is available Release date: 2024/04/16
Lead time: In stock, ready for shipment Packaging: bag/bottle/drum/IBC
Delivery: By express, by air, by sea Origin: Manufacturer, advantage product
COA, MSDS: Available, contact us for details Name: Tina

 1. Materials information

 Names

Namevalproic acid
SynonymMore Synonyms

 Valproic acid Biological Activity

DescriptionValproic acid is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2; Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
Related Catalog
Signaling Pathways >> Autophagy >> Autophagy
Signaling Pathways >> Cell Cycle/DNA Damage >> HDAC
Signaling Pathways >> Epigenetics >> HDAC
Signaling Pathways >> Autophagy >> Mitophagy
Natural Products >> Acids and Aldehydes
Research Areas >> Cancer
Target

HDAC1:400 μM (IC50)

HDAC:0.5-2 mM (IC50)

HDAC2

Autophagy

Mitophagy

In VitroValproic acid inhibits the growth dose- and time-dependently with an IC50 of appr 10 and 4 mM at 24 and 72 h, respectively. Valproic acid significantly attenuates the activities of total, cytosol and nuclear HDACs. Valproic acid increases the form of acetylated histone 3 in HeLa cells. Valproic acid (1-3 mM) induces a G1 phase arrest, while 10 mM Valproic acid significantly induces a G2/M phase arrest of cell cycle in HeLa cells. In addition, Valproic acid increases the percentage of sub-G1 cells in HeLa cells in a dose-dependent manner at 24 h[1]. Valproic acid inhibits the mRNA and protein expression of VEGF, VEGFR2 and bFGF. Valproic acid inhibits the protein expression of HDAC1, increases histone H3 acetylation, and enhances the accumulation of hyperacetylated histone H3 on VEGF promoters[2]. Valproic acid treatment results in increased levels of phosphorylated AMPK/ACC in primary mouse hepatocytes. Phosphorylation of ACC following Valproic acid treatment is AMPK-dependent. Valproic acid inhibits the deacetylase activity of both mouse liver nuclear extracts and human recombinant HDAC1 while of the metabolites of Valproic acid, only 2-ene-Valproic acid and 4-ene-Valproic acid diminish deacetylase activity[4].
In VivoValproic acid (500 mg/kg, i.p.) inhibits the tumor growth and angiogenesisin the mice transplanted with Kasumi-1 cells. The IR rate in the Valproic acid group is 57.25% at the end of the experiment[2]. Valproic acid (350 mg/kg, i.p.) demonstrates more social investigation and play fighting than control animals[3].
Kinase AssayThe activity of caspase-3, -8 and -9 is assessed using the caspase-3, -8 and -9 colorimetric assay kits, respectively. In brief, 1×106 cells in a 60-mm culture dish are incubated with 10 mM Valproic acid for 24 h. The cells are then washed in PBS and suspended in 5 volumes of lysis buffer provided with the kit. Protein concentrations are determined using the Bradford method. Supernatants containing 50 μg total protein are used to determine caspase-3, -8 and -9 activities. The supernatants are added to each well in 96-well microtiter plates with DEVD-pNA, IETD-pNA or LEHD-pNA as caspase-3, -8 and -9 substrates and the plates are incubated at 37°C for 1 h. The optical density of each well is measured at 405 nm using a microplate reader. The activity of caspase-3, -8 and -9 is expressed in arbitrary absorbance units.
Cell AssayIn brief, 5×105 cells are seeded in 96-well microtiter plates for MTT assays. After exposure to the designated doses of Valproic acid for the indicated times, MTT solution [20 mL: 2 mg/mL in phosphate-buffered saline (PBS)] is added to each well of the 96-well plates. The plates are additionally incubated for 3 h at 37°C. Medium is withdrawn from the plates by pipetting and 200 mL DMSO is added to each well to solubilize the formazan crystals. The optical density is measured at 570 nm using a microplate reader.
Animal AdminSplenectomies are performed on the BALB/c nude mice. One week after the splenectomies, the mice receiv whole body irradiation with 137Cs at a dose of 4 Gy. At 48-72 h post-irradiation, the mice are subcutaneously implanted with Kasumi-1 cells (2×107 cells/mouse with 0.15-0.2 mL) in the right axillary region. The mice are randomLy assigned to two groups, the Valproic acid (n=6) and control (n=6) groups. When the tumors are appr 200 mm3 in size at appr 10 days post-implantation, 0.2 mL Valproic acid (500 mg/kg body weight) or 0.2 mL saline is injected intraperitoneally every day. Valproic acid is dissolved in saline at a concentration of 25 mg/mL. The longest diameter (a) and the shortest diameter (b) of the tumor are measured every three days, and the tumor volume (TV) is calculated according to the following formula: TV=1/2×a×b2. Following two weeks of injections, the mice are sacrificed by cervical dislocation and the tumor masses are removed for the following experiments.
References

[1]. Han BR, et al. Valproic acid inhibits the growth of HeLa cervical cancer cells via caspase-dependent apoptosis. Oncol Rep. 2013 Dec;30(6):2999-3005.

[2]. Zhang ZH, et al. Valproic acid inhibits tumor angiogenesis in mice transplanted with Kasumi 1 leukemia cells. Mol Med Rep. 2013 Nov 28.

[3]. Cohen OS, et al. Acute prenatal exposure to a moderate dose of valproic acid increases social behavior and alters gene expression in rats. Int J Dev Neurosci. 2013 Dec;31(8):740-50.

[4]. Avery LB, et al. Valproic Acid Is a Novel Activator of AMP-Activated Protein Kinase and Decreases Liver Mass, Hepatic Fat Accumulation, and Serum Glucose in Obese Mice. Mol Pharmacol. 2014 Jan;85(1):1-10.

[5]. Valproic acid, et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001 Sep 28;276(39):36734-41.

 Chemical & Physical Properties

Density0.9±0.1 g/cm3
Boiling Point220.0±0.0 °C at 760 mmHg
Melting Point120 - 130ºC
Molecular FormulaC8H16O2
Molecular Weight144.211
Flash Point111.1±0.0 °C
Exact Mass144.115036
PSA37.30000
LogP2.72
Vapour Pressure0.0±0.9 mmHg at 25°C
Index of Refraction1.435
Water Solubilityslightly soluble

 MSDS

Valproic acid MSDS(Chinese)

 Toxicological Information

CHEMICAL IDENTIFICATION

  • RTECS NUMBER :

  • YV7875000

  • CHEMICAL NAME :

  • Valeric acid, 2-propyl-

  • CAS REGISTRY NUMBER :

  • 99-66-1

  • BEILSTEIN REFERENCE NO. :

  • 1750447

  • LAST UPDATED :

  • 199712

  • DATA ITEMS CITED :

  • 43

  • MOLECULAR FORMULA :

  • C8-H16-O2

  • MOLECULAR WEIGHT :

  • 144.24

  • WISWESSER LINE NOTATION :

  • QVY3&3

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human - child

  • DOSE/DURATION :

  • 375 mg/kg

  • TOXIC EFFECTS :

  • Cardiac - pulse rate increase, without fall in BP Vascular - BP lowering not characterized in autonomic section Lungs, Thorax, or Respiration - cyanosis

  • REFERENCE :

  • CCMDC7 Critical Care Medicine. (Williams & Wilkins, 428 E. Preston Street, Baltimore, MD 21202) V.1- 1973- Volume(issue)/page/year: 21,299,1993

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human - child

  • DOSE/DURATION :

  • 412 mg/kg

  • TOXIC EFFECTS :

  • Behavioral - coma Cardiac - pulse rate increase, without fall in BP Lungs, Thorax, or Respiration - dyspnea

  • REFERENCE :

  • JATOD3 Journal of Analytical Toxicology. (Preston Pub. Inc., POB 48312, Niles, IL 60648) V.1- 1977- Volume(issue)/page/year: 20,55,1996

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human - child

  • DOSE/DURATION :

  • 10500 mg/kg/30W-I

  • TOXIC EFFECTS :

  • Gastrointestinal - changes in structure or function of endocrine pancreas Gastrointestinal - nausea or vomiting

  • REFERENCE :

  • AJDCAI American Journal of Diseases of Children. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1-80(3), 1911-50; V.100- 1960- Volume(issue)/page/year: 138,912,1984

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human - man

  • DOSE/DURATION :

  • 21 mg/kg/2D-I

  • TOXIC EFFECTS :

  • Behavioral - somnolence (general depressed activity) Nutritional and Gross Metabolic - other changes

  • REFERENCE :

  • NEURAI Neurology. (Modern Medicine Pub., Inc., 1 E. First St., Duluth, MN 55802) V.1- 1951- Volume(issue)/page/year: 37,886,1987

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Unreported

  • SPECIES OBSERVED :

  • Human - child

  • DOSE/DURATION :

  • 1800 mg/kg/60D

  • TOXIC EFFECTS :

  • Gastrointestinal - changes in structure or function of endocrine pancreas Gastrointestinal - nausea or vomiting

  • REFERENCE :

  • LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 1,1196,1980

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human

  • DOSE/DURATION :

  • 13333 ug/kg/D-I

  • TOXIC EFFECTS :

  • Behavioral - sleep

  • REFERENCE :

  • NEJMAG New England Journal of Medicine. (Massachusetts Medical Soc., 10 Shattuck St., Boston, MA 02115) V.198- 1928- Volume(issue)/page/year: 301,435,1979

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 670 mg/kg

  • TOXIC EFFECTS :

  • Behavioral - somnolence (general depressed activity) Gastrointestinal - hypermotility, diarrhea

  • REFERENCE :

  • FCTXAV Food and Cosmetics Toxicology. (London, UK) V.1-19, 1963-81. For publisher information, see FCTOD7. Volume(issue)/page/year: 2,327,1964

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 1098 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • REFERENCE :

  • EPXXDW European Patent Application. (U.S. Patent and Trademark Office, Foreign Patents, Washington, DC 20231) Volume(issue)/page/year: #78785

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 470 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • REFERENCE :

  • CHTPBA Chimica Therapeutica. (Paris, France) V.1-8, 1965-73. For publisher information, see EJMCA5. Volume(issue)/page/year: 3,430,1968

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Subcutaneous

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 860 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • REFERENCE :

  • 85GNAW "Pharmacodynamie de l'Acide Dipropylacetique (ou Propyl-2-Pentanoique) et de ses Amides," Carraz, G., Imprimerie Eymond, 1968 Volume(issue)/page/year: -,38,1968

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • SPECIES OBSERVED :

  • Rodent - rabbit

  • DOSE/DURATION :

  • 1200 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • REFERENCE :

  • 85GNAW "Pharmacodynamie de l'Acide Dipropylacetique (ou Propyl-2-Pentanoique) et de ses Amides," Carraz, G., Imprimerie Eymond, 1968 Volume(issue)/page/year: -,39,1968

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - guinea pig

  • DOSE/DURATION :

  • 824 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • REFERENCE :

  • 85GNAW "Pharmacodynamie de l'Acide Dipropylacetique (ou Propyl-2-Pentanoique) et de ses Amides," Carraz, G., Imprimerie Eymond, 1968 Volume(issue)/page/year: -,39,1968 ** REPRODUCTIVE DATA **

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 5480 mg/kg

  • SEX/DURATION :

  • female 1-39 week(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system

  • REFERENCE :

  • AEPEDI Anales Espanoles de Pediatria. (Asociacion Espanola de Pediatria, Apartado 1176, 28028 Madrid, Spain) V.1- 1968- Volume(issue)/page/year: 39,19,1993

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 720 mg/kg

  • SEX/DURATION :

  • female 1-90 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - Central Nervous System

  • REFERENCE :

  • CPEDAM Clinical Pediatrics (Philadelphia). (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740) V.1- 1962- Volume(issue)/page/year: 22,336,1983

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 6525 mg/kg

  • SEX/DURATION :

  • female 26 week(s) pre-mating female 1-36 week(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - biochemical and metabolic Reproductive - Effects on Newborn - physical

  • REFERENCE :

  • CPEDAM Clinical Pediatrics (Philadelphia). (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740) V.1- 1962- Volume(issue)/page/year: 23,352,1984

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Unreported

  • DOSE :

  • 126 gm/kg

  • SEX/DURATION :

  • female 1-18 week(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • REFERENCE :

  • FDTHES Fetal Diagnosis and Therapy (Basel). (S. Karger, Postfach. CH-4009 Basel, Switzerland) V.5- 1990- Volume(issue)/page/year: 9,155,1994

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Unreported

  • DOSE :

  • 2394 mg/kg

  • SEX/DURATION :

  • female 1-36 week(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Newborn - Apgar score (human only)

  • REFERENCE :

  • JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 219,768,1981

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Unreported

  • DOSE :

  • 2047 mg/kg

  • SEX/DURATION :

  • female 27-40 week(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Newborn - physical

  • REFERENCE :

  • JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 219,768,1981

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Unreported

  • DOSE :

  • 5320 mg/kg

  • SEX/DURATION :

  • female 2-39 week(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

  • REFERENCE :

  • JOPDAB Journal of Pediatrics. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63141) V.1- 1932- Volume(issue)/page/year: 97,332,1980

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Unreported

  • DOSE :

  • 5320 mg/kg

  • SEX/DURATION :

  • female 2-39 week(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - skin and skin appendages Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system

  • REFERENCE :

  • JOPDAB Journal of Pediatrics. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63141) V.1- 1932- Volume(issue)/page/year: 97,332,1980

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Unreported

  • DOSE :

  • 5320 mg/kg

  • SEX/DURATION :

  • female 2-39 week(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)

  • REFERENCE :

  • JOPDAB Journal of Pediatrics. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63141) V.1- 1932- Volume(issue)/page/year: 97,332,1980

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 600 mg/kg

  • SEX/DURATION :

  • female 13 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

  • REFERENCE :

  • TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 45,603,1992

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 34 gm/kg

  • SEX/DURATION :

  • male 60 day(s) pre-mating female 2 week(s) pre-mating - 1 day(s) post-birth

  • TOXIC EFFECTS :

  • Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

  • REFERENCE :

  • PBPSDY Pharmacological and Biochemical Properties of Drug Substances. (American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC 20037) V.1- 1977- Volume(issue)/page/year: 2,58,1979

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 2400 mg/kg

  • SEX/DURATION :

  • female 7-18 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - Central Nervous System

  • REFERENCE :

  • NETEEC Neurotoxicology and Teratology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.9- 1987- Volume(issue)/page/year: 13,471,1991

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 6 gm/kg

  • SEX/DURATION :

  • female 8-17 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Specific Developmental Abnormalities - urogenital system

  • REFERENCE :

  • TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 35,28A,1987

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Subcutaneous

  • DOSE :

  • 660 mg/kg

  • SEX/DURATION :

  • female 10 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

  • REFERENCE :

  • ARTODN Archives of Toxicology. (Springer-Verlag, Heidelberger Pl. 3, D-1000 Berlin 33, Fed. Rep. Ger.) V.32- 1974- Volume(issue)/page/year: 64,545,1990

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 1500 mg/kg

  • SEX/DURATION :

  • female 6-15 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • REFERENCE :

  • PBPSDY Pharmacological and Biochemical Properties of Drug Substances. (American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC 20037) V.1- 1977- Volume(issue)/page/year: 2,58,1979

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • DOSE :

  • 432 mg/kg

  • SEX/DURATION :

  • female 11-13 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

  • REFERENCE :

  • TCMUD8 Teratogenesis, Carcinogenesis, and Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1980- Volume(issue)/page/year: 1,367,1981

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • DOSE :

  • 432 mg/kg

  • SEX/DURATION :

  • female 8-10 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • REFERENCE :

  • TCMUD8 Teratogenesis, Carcinogenesis, and Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1980- Volume(issue)/page/year: 1,367,1981

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • DOSE :

  • 519 mg/kg

  • SEX/DURATION :

  • female 8-10 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - Central Nervous System

  • REFERENCE :

  • TCMUD8 Teratogenesis, Carcinogenesis, and Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1980- Volume(issue)/page/year: 1,367,1981

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • DOSE :

  • 600 mg/kg

  • SEX/DURATION :

  • female 9 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

  • REFERENCE :

  • AJMGDA American Journal of Medical Genetics. (John Wiley & Sons Ltd., 605 Third Ave., New York, NY 10158) V.1- 1977- Volume(issue)/page/year: 70,303,1997

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Subcutaneous

  • DOSE :

  • 2400 mg/kg

  • SEX/DURATION :

  • female 7-14 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - Central Nervous System

  • REFERENCE :

  • LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 1,763,1983

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Unreported

  • DOSE :

  • 600 mg/kg

  • SEX/DURATION :

  • female 8 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

  • REFERENCE :

  • TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 35,29A,1987

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 18 gm/kg

  • SEX/DURATION :

  • female 21-50 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Embryo or Fetus - fetal death

  • REFERENCE :

  • TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 33,45A,1986

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 4550 mg/kg

  • SEX/DURATION :

  • female 6-18 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

  • REFERENCE :

  • PBPSDY Pharmacological and Biochemical Properties of Drug Substances. (American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC 20037) V.1- 1977- Volume(issue)/page/year: 2,58,1979

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 4550 mg/kg

  • SEX/DURATION :

  • female 6-18 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system

  • REFERENCE :

  • PBPSDY Pharmacological and Biochemical Properties of Drug Substances. (American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC 20037) V.1- 1977- Volume(issue)/page/year: 2,58,1979

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 1950 mg/kg

  • SEX/DURATION :

  • female 6-18 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

  • REFERENCE :

  • PBPSDY Pharmacological and Biochemical Properties of Drug Substances. (American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC 20037) V.1- 1977- Volume(issue)/page/year: 2,58,1979

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Unreported

  • DOSE :

  • 945 mg/kg

  • SEX/DURATION :

  • female 6-8 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - urogenital system

  • REFERENCE :

  • 36DLAV "Clinical and Pharmacological Aspects of Sodium Valproate (Epilim) in the Treatment of Epilepsy, Proceedings of a Symposium, Nottingham, UK, 1975," Legg, N.J., et al., eds., Kent, UK, MCS Consultants, 1976 Volume(issue)/page/year: -,105,1976

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • DOSE :

  • 300 mg/kg

  • SEX/DURATION :

  • female 7 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - Central Nervous System

  • REFERENCE :

  • TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 29(2),47A,1984 *** REVIEWS *** TOXICOLOGY REVIEW JOPDAB Journal of Pediatrics. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63141) V.1- 1932- Volume(issue)/page/year: 97,333,1980 TOXICOLOGY REVIEW PBPSDY Pharmacological and Biochemical Properties of Drug Substances. (American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC 20037) V.1- 1977- Volume(issue)/page/year: 2,58,1979 TOXICOLOGY REVIEW APJUA8 Acta Pharmaceutica Jugoslavica. (FDH, Masarykova 2, 41000 Zagreb, Yugoslavia) V.1-41, 1951-1991. Volume(issue)/page/year: 41,79,1991 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3895 No. of Facilities: 245 (estimated) No. of Industries: 4 No. of Occupations: 6 No. of Employees: 5848 (estimated) No. of Female Employees: 3255 (estimated)

 Safety Information

SymbolArticle illustration Article illustration
GHS07, GHS08
Signal WordDanger
Hazard StatementsH302-H315-H319-H335-H360
Precautionary StatementsP201-P280-P301 + P312 + P330-P305 + P351 + P338-P308 + P313
Personal Protective EquipmentEyeshields;Faceshields;full-face respirator (US);Gloves;multi-purpose combination respirator cartridge (US);type ABEK (EN14387) respirator filter
Hazard CodesXn:Harmful
Risk PhrasesR22;R36/37/38
Safety PhrasesS26-S45-S36/37-S16
RIDADRUN 1230 3/PG 2
WGK Germany3
RTECSYV7875000
Packaging GroupIII
Hazard Class8
HS Code2915600000

 Synthetic Route

Previous 1/9 Next
Article illustration

2,2-Dipropylmal...

1636-27-7

~99%

Article illustration

Valproic acid

99-66-1

Literature: CALYX CHEMICALS AND PHARMACEUTICALS LTD. Patent: WO2008/62471 A2, 2008 ; Location in patent: Page/Page column 10 ;
Article illustration

2,2-dipropyl-ac...

76002-02-3

Article illustration

Ethyl acetoacet...

141-97-9

Article illustration

1-Bromopropane

106-94-5

~%

Article illustration

Valproic acid

99-66-1

Literature: US5856569 A1, ;
Article illustration

ethyl 2-propylp...

17022-31-0

~%

Article illustration

Valproic acid

99-66-1

Literature: Journal of the American Chemical Society, , vol. 87, # 6 p. 1297 - 1307

 Precursor & DownStream

Precursor  10

Previous 1/3 Next

  • Article illustration CAS#:1636-27-7
    2,2-Dipropylmal...

  • Article illustration CAS#:13310-75-3
    2-propylvaleron...

  • Article illustration CAS#:76002-02-3
    2,2-dipropyl-ac...

  • Article illustration CAS#:141-97-9
    Ethyl acetoacetate

DownStream  10

Previous 1/3 Next

  • Article illustration CAS#:22632-59-3
    methyl 2-propyl...

  • Article illustration CAS#:2751-06-6
    N-tert-butyl-2-...

  • Article illustration CAS#:2936-13-2
    N-butyl-2-propy...

  • Article illustration CAS#:2653-58-9
    1-morpholin-4-y...

 Customs

HS Code2915900090
Summary2915900090 other saturated acyclic monocarboxylic acids and their anhydrides, halides, peroxides and peroxyacids; their halogenated, sulphonated, nitrated or nitrosated derivatives VAT:17.0% Tax rebate rate:9.0% Supervision conditions:AB(certificate of inspection for goods inward,certificate of inspection for goods outward) MFN tariff:5.5% General tariff:30.0%

 Articles227

More Articles
Synergism of arsenic trioxide and MG132 in Raji cells attained by targeting BNIP3, autophagy, and mitochondria with low doses of valproic acid and vincristine.

Eur. J. Cancer 50(18) , 3243-61, (2014)

We previously demonstrated that arsenic trioxide (ATO) and proteasome inhibitor MG132 synergistically induced cell death in promonocytic leukaemia cell line U937 but were antagonistic in Burkitt's lym...

Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.

Breast Cancer Res. 17 , 26, (2015)

The emergence of hormone therapy resistance, despite continued expression of the estrogen receptor (ER), is a major challenge to curing breast cancer. Recent clinical studies suggest that epigenetic m...

HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity.

Hum. Mol. Genet. 24 , 3257-71, (2015)

Huntington's disease (HD) is a fatal neurodegenerative disease, caused by expansion of polyglutamine repeats in the Huntingtin gene, with longer expansions leading to earlier ages of onset. The HD iPS...

 Synonyms

Pentanoic acid, 2-propyl-
Mylproin
Ergenyl
MFCD00879852
2-Propylpentanoic acid
2-Propylvaleric Acid
Depakine
di-n-propyl-acetic acid
Valproic acid
Depakene
2-n-Propylpentanoic acid
Valproate
[3H]-Valproic acid
Convulex
Valeric acid, 2-propyl-
Valproic-250
2,2-BIS(TRIFLUOROMETHYL)PROPIONIC ACID
Dipropylacetic acid
[14C]-Valproic acid
2-propyl-pentanoic acid
EINECS 202-777-3
sodium valproate


2. Packaging of materials

  • For powders: normal is 25kgs/Drum or bag, or larger/smaller package as request.

  • For liquids: normal 25kgs/drum, 180-300kgs/bucket, or IBC, determined by the nature of the product. 

                             Or smaller package 1kg/bottle, 10kgs/bottle as request. 


Article illustrationArticle illustration


3. Shipping & Delivery

  • By Express

Provide door to door service

Suitable for goods under 50kg

Delivery: 3-7 days

Cost: low cost

Article illustration


  • By Air

Provide airport to airport service

Suitable for goods over 50kg

Delivery: 3-14 days

Cost: high cost

Article illustration


  • By Sea

Provide seaport to seaport service

Suitable for goods over 100kg

Delivery: 2-45 days

Cost: low cost

Article illustration


4. Contact information

For more details, pls contact us freely.

Email address: Tina@fdachem.com

Mob: 86 13213167925

WhatsApp/Skype/Wechat/LINE: 86 13213167925



Company Profile Introduction

Henan Fengda Chemical Co., Ltd. is located in the High-tech Development Zone of Henan Province. Specializing in the production and sales of various fine chemical products required for industrial production, including chemical raw materials, organic raw materials, petrochemicals, chemical reagents, solvents, catalysts, and additives, etc.

You may like

Recommended supplier

Product name Price   Suppliers Update time
valproic acid
 $0.00/1kg
VIP4Y
Hebei Yanxi Chemical Co., Ltd.
 2023-10-10
2-Propylpentanoic acid
 $0.00/25KG
VIP4Y
Hebei Mojin Biotechnology Co., Ltd
 2023-09-11
2-Propylpentanoic acid
 $10.00/1KG
VIP3Y
Hebei Guanlang Biotechnology Co,.LTD
 2023-06-08
2-Propylpentanoic acid
 $1.00/1kg
VIP2Y
Hebei Duling International Trade Co. LTD
 2022-11-25
2-Propylpentanoic acid
 $10.00/1KG
VIP6Y
Hebei Guanlang Biotechnology Co., Ltd.
 2022-09-16
valproic acid
 $150.00/1ASSAYS
Hebei Mingeng Biotechnology Co., Ltd
 2021-10-28
2-Propylpentanoic acid USP/EP/BP
 $1.10/1g
VIP4Y
Dideu Industries Group Limited
 2021-07-22
Valproic acid
 $15.00/1KG
Zhuozhou Wenxi import and Export Co., Ltd
 2021-07-10
Valproic acid
 $1.00/1KG
Shijiazhuang Erche Biotechnology Co., Ltd
 2021-06-28
Valproic acid
 $69.00/1KG
Hebei shuoxi biotechnology co. LTD
 2019-10-22

Henan Fengda Chemical Co., Ltd

1YR ChinaChina
webchat
  • Since: 2023-02-10
  • Address: Room 01, 2288 E05, Building 14, East Henan University, Science and Technology Park, 279 Xisanhuan Ro
INQUIRY